First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

dc.contributor.authorPeters, S.
dc.contributor.authorScherpereel, A.
dc.contributor.authorCornelissen, R.
dc.contributor.authorOulkhouir, Y.
dc.contributor.authorGreillier, L.
dc.contributor.authorKaplan, M. A.
dc.contributor.authorTalbot, T.
dc.date.accessioned2024-04-24T16:10:49Z
dc.date.available2024-04-24T16:10:49Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.descriptionCongress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 16-21, 2021 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncol,Japanese Soc Med Oncolen_US
dc.description.sponsorshipBristol Myers Squibben_US
dc.description.sponsorshipBristol Myers Squibb.en_US
dc.identifier.doi10.1016/j.annonc.2021.08.2146
dc.identifier.endpageS1342en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1341en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2021.08.2146
dc.identifier.urihttps://hdl.handle.net/11468/15130
dc.identifier.volume32en_US
dc.identifier.wosWOS:000700527704025
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keyword]en_US
dc.titleFirst-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743en_US
dc.titleFirst-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
dc.typeConference Objecten_US

Dosyalar